Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
{{output}}
Recurrent glioblastoma (rGBM) remains incurable. One barrier to the development of effective rGBM therapies is the difficulty in collecting posttreatment tumor tissue. Serial multiomic assays from longitudinal rGBM biopsies may uncover tumor responses to a tre... ...
